Bicycle Therapeutics (BCYC)

• Market cap: $543M
• 1 day: -7.54%
• 5 days: -11.30%
• 1 month: -25.02%
• 3 months: -45.33%
• 6 months: -65.43%
• Year to date: -45.33%
• 1 year: -67.63%
• 5 years: -43.85%
• 10 years: -34.58%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Employees: 305

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

2.94% more ownership

Funds ownership: 85.16% [Q3] → 88.1% (+2.94%) [Q4]

8% less funds holding

Funds holding: 105 [Q3] → 97 (-8) [Q4]

17% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 35

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

36% less capital invested

Capital invested by funds: $915M [Q3] → $586M (-$329M) [Q4]

42% less call options, than puts

Call options by funds: $148K | Put options by funds: $256K

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 91% upside
• Avg. target: $26 231% upside
• High target: $33 320% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Needham Ami Fadia 29% 1-year accuracy 50 / 171 met price target	282% upside $30	Buy Reiterated	11 Mar 2025
Citizens Capital Markets Reni Benjamin 14% 1-year accuracy 5 / 37 met price target	231% upside $26	Market Outperform Reiterated	26 Feb 2025
HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 45 / 200 met price target	320% upside $33	Buy Reiterated	26 Feb 2025
Stephens & Co. Sudan Loganathan 22% 1-year accuracy 6 / 27 met price target	91% upside $15	Equal-Weight Reiterated	22 Jan 2025